Canada lub sij hawm 2022-01-24, RhoVac, lub tuam txhab kws tshuaj tsom rau cov qog noj ntshav, tshaj tawm tias nws daim ntawv thov patent (No. 2710061) rau nws cov tshuaj tiv thaiv kab mob qog noj ntshav RV001 yuav tau tso cai los ntawm Canadian Intellectual Property Office (CIPO).Yav dhau los, lub tuam txhab tau txais patents ntsig txog RV001 hauv Tebchaws Meskas, Europe thiab Nyiv.Qhov nyiaj pab patent no yuav muab kev tiv thaiv dav dav rau RV001 hauv kev lag luam tseem ceeb thiab txhawb nqa lub tuam txhab patent teeb meem.
Ib yam li daim ntawv thov patent yav dhau los, daim ntawv pov thawj no npog cov tshuaj tiv thaiv kab mob qog noj ntshav RV001 thiab nws cov kev hloov pauv, nrog rau kev siv hauv kev kho mob / tiv thaiv RhoC-kev qhia txog kev mob qog noj ntshav.Ntawm lawv, RhoC yog cov qog nqaij hlav txuam nrog antigen (TAA) uas tau nthuav tawm ntau dhau ntawm ntau hom qog cell.Thaum pom zoo, patent yuav tas rau xyoo 2028-12 thiab xav tias yuav txuas ntxiv thaum tau txais Daim Ntawv Pov Thawj Kev Tiv Thaiv Ntxiv (CSP).
01 Onilcamotide
Onilcamotide yog cov tshuaj tiv thaiv kab mob qog noj ntshav uas muaj cov tshuaj tiv thaiv kab mob peptides tau los ntawm Ras homologous tsev neeg C (RhoC), uas tuaj yeem ua rau emulsified hauv lub cev tiv thaiv kab mob adjuvant montanide ISA-51, muaj peev xwm immunomodulatory thiab antitumor cov dej num.Kev tswj hwm subcutaneous ntawm Onilcamotide txhawb nqa lub cev tiv thaiv kab mob txhawm rau txhim kho kev lom zem thiab cytotoxic T lymphocyte (CTL) cov lus teb rau RhoC-qhia cov qog hlwb, yog li lysing cov qog hlwb.
2020-11, RV001 tau tso cai Fast Track xaiv los ntawm FDA.
02 Kev sim tshuaj kho mob
Hauv 2018, Phase I / IIa kev soj ntsuam ntawm Onilcamotide rau kev kho mob qog noj ntshav tau pom zoo, thiab tag nrho ntawm 21 tus neeg mob tau cuv npe.Cov txiaj ntsig tau pom tias Onilcamotide muaj kev nyab xeeb thiab zam tau zoo.Tsis tas li ntawd, cov neeg mob tau tsim muaj zog thiab ruaj khov tiv thaiv teb tom qab kev kho mob.Xyoo 2021, kev soj ntsuam ntawm 19 ntawm cov kev kawm no, peb xyoos tom qab ua tiav kev kho mob los ntawm RhoVac, pom tias cov kev kawm no tsis tau tsim muaj cov metastases lossis tau txais kev kho mob ntxiv thiab tsis muaj qhov tseem ceeb ntawm prostate-specific antigen (PSA) kev loj hlob..Ntawm cov no, 16 cov kev kawm tsis tau kuaj pom PSA, thiab 3 yam kev kawm tau qeeb PSA.PSA yog ib qho protein uas tsim los ntawm lub caj pas prostate thiab siv los taug qab qhov kev mob qog noj ntshav prostate paub.
Xyoo 2019, RV001 Phase IIb kho mob BraVac (randomized, ob qhov muag tsis pom kev, tshuaj placebo-tswj) tau pib los ntsuas nws cov txiaj ntsig hauv kev tiv thaiv lossis txwv kev loj hlob ntawm metastatic prostate cancer tom qab phais / hluav taws xob.Qhov kev sim IIb no yog kev kawm thoob ntiaj teb, ntau lub chaw kawm nrhiav neeg ua haujlwm hauv 6 lub tebchaws nyob sab Europe (Denmark, Finland, Sweden, Belgium, Lub Tebchaws Yelemees, thiab United Kingdom) thiab Tebchaws Meskas.Qhov kev sim ua tiav kev nrhiav neeg ua haujlwm hauv 2021-09, nrog rau tag nrho kwv yees li 175 yam kev kawm, thiab yuav xaus rau xyoo 2022H1.Tsis tas li ntawd, RhoVac npaj yuav ua cov kev tshawb fawb soj ntsuam ua ntej txhawm rau muab cov ntaub ntawv pov thawj rau kev nthuav dav ntawm RV001 hauv kev qhia.
Tsis tas li ntawd, pawg saib xyuas kev nyab xeeb kuj tau ua qhov kev ntsuam xyuas kev nyab xeeb ib ntus ntawm RV001 hauv 2021-07, thiab tsis pom muaj qhov tshwm sim tsis zoo tshwm sim, uas tau ua raws li qhov kev soj ntsuam ntawm theem I / II yav dhau los.
Post lub sij hawm: Feb-17-2022